Medincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress
31 Juillet 2024 - 6:30PM
Business Wire
Medincell (Paris:MEDCL):
Olanzapine LAI (mdc-TJK)
- No PDSS* observed after completion of c.95% of the targeted
injections for submission
- Full phase 3 safety results on track for H2 2024
- Positive phase 3 efficacy results have already been
announced in May 2024 (read the full PR)
UZEDY®
- Reaffirming revenue guidance for 2024: c.$80
million
- Exploring an additional indication for UZEDY® for the
treatment of Bipolar I Disorder in adults
ACCESS HERE THE FULL PRESS RELEASE
*PDSS = Post injection Delirium/Sedation Syndrome
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical
licensing company developing long-acting injectable drugs in many
therapeutic areas. Our innovative treatments aim to guarantee
compliance with medical prescriptions, to improve the effectiveness
and accessibility of medicines, and to reduce their environmental
footprint. They combine active pharmaceutical ingredients with our
proprietary BEPO® technology which controls the delivery of a drug
at a therapeutic level for several days, weeks or months from the
subcutaneous or local injection of a simple deposit of a few
millimeters, entirely bioresorbable. The first treatment based on
BEPO® technology, intended for the treatment of schizophrenia, was
approved by the FDA in April 2023, and is now distributed in the
United States by Teva under the name UZEDY® (BEPO® technology is
licensed to Teva under the name SteadyTeq™). We collaborate with
leading pharmaceutical companies and foundations to improve global
health through new treatment options. Based in Montpellier,
Medincell currently employs more than 140 people representing more
than 25 different nationalities.
UZEDY® and SteadyTeq™ are registered trademarks of Teva
Pharmaceuticals.
www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731324476/en/
David Heuzé - Head of Corporate and Financial Communications,
and ESG david.heuze@medincell.com / +33 (0)6 83 25 21 86
Grace Kim - Head of US Financial Strategy and IR
grace.kim@medincell.com / +1 (646) 991-4023
Investors Relations France Louis-Victor
Delouvrier/Alban Dufumier medincell@newcap.eu / +33 (0)1 44 71
94 94
Media Relations Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Medincell (EU:MEDCL)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024